Clobetasol: Nursing Drug Guide, HPA Suppression & Hold Rules

Clobetasol propionate is a topical-only super-high-potency corticosteroid. Verify the MAR matches the dispensed product—cream, ointment, gel, foam, and solution formulations share potency limits but may differ in vehicle and site suitability.

• Temovate — clobetasol propionate 0.05% cream, ointment, gel, and topical solution
• Clobex — clobetasol propionate 0.05% shampoo, spray, and lotion
• Olux / Olux-E — clobetasol propionate 0.05% foam
• Impoyz — clobetasol propionate 0.025% cream (plaque psoriasis, adults 18+ per labeling)
• Generic clobetasol propionate — 0.05% and 0.025% topical products

Do not confuse topical clobetasol with oral or injectable glucocorticoids on the MAR. Super-high potency topical products are not interchangeable with lower-potency creams without prescriber review.

Clobetasol is reserved for inflammatory dermatoses that have not responded adequately to lower-potency topical corticosteroids. Nursing focus is short-course use on the smallest effective area with strict duration and quantity limits.

↔On a small screen, swipe or scroll sideways to see the full table.

Clobetasol propionate is a synthetic glucocorticoid analog of prednisolone with very high glucocorticoid activity and slight mineralocorticoid activity. Topical application binds glucocorticoid receptors in skin and can be absorbed systemically—especially with potency, duration, body surface area (BSA), and occlusion.

Absorbed clobetasol suppresses endogenous cortisol production through HPA axis feedback. That pharmacology drives the 2-week duration cap, 50 g/week quantity limit, and nursing vigilance for Cushingoid features, hyperglycemia, and withdrawal after abrupt stop.

Doses below are from reviewed DailyMed prescribing information—always verify the specific product label and prescriber order.

Clobetasol propionate 0.05% — general dermatologic use

0.05% cream USP: Do not use occlusive dressings. HPA axis suppression occurred when 2 g/day was applied for 1 week in patients with eczema—a reminder that even labeled non-occluded use on inflamed skin can absorb significantly.

Clobetasol propionate 0.025% cream — plaque psoriasis (adults 18+)

Apply a thin layer twice daily to affected areas for up to 2 consecutive weeks. Do not exceed 50 g/week. Avoid face, scalp, axilla, and groin unless prescriber directs otherwise.

Pretreatment checks

• Confirm topical product and strength on the MAR—clobetasol is for external dermatologic use only, not oral or injectable routes
• Measure or estimate treated BSA; document days of consecutive use and grams used this week—misuse beyond 2 weeks, 50 g/week, large areas, or occlusion increases HPA suppression and skin atrophy risk
• Perform medication reconciliation for duplicate topical, inhaled, or systemic corticosteroids (e.g., home triamcinolone, prednisone)
• Inspect application sites for existing atrophy, striae, or infection—do not apply over untreated bacterial, fungal, or viral skin infection unless prescriber directs concurrent therapy
• Review diabetes history; plan glucose surveillance when large areas, occlusion, or prolonged use is present
• Verify pregnancy/lactation status and nipple-adjacent treatment plans

Contraindications

• Hypersensitivity to clobetasol propionate or any component of the specific product
• Do not apply if skin atrophy is present at the intended site (0.025% labeling guidance)

Important interactions and warnings

↔On a small screen, swipe or scroll sideways to see the full table.

• Apply a thin layer to affected skin only—more product increases absorption without proportional benefit
• Follow medication administration rights; document product, strength, sites treated, amount used, and time
• Wash hands after application unless treating the hands; avoid contact with eyes and mucous membranes
• Do not use occlusive dressings with 0.05% cream USP unless a specific prescriber order and product labeling support it
• Do not apply to open wounds, broken skin with uncontrolled infection, or face/scalp/axilla/groin on 0.025% plaque-psoriasis labeling unless directed
• Perform baseline and ongoing skin assessment at treated sites—document erythema, thickness, striae, atrophy, and infection signs
• Coordinate with wound care plans when dermatitis overlaps broken or ulcerated skin—clobetasol is not a substitute for infection management

• Reduced erythema, scaling, and pruritus of corticosteroid-responsive plaques within days when used appropriately on limited areas
• Improved patient comfort and sleep when severe pruritus was the primary complaint
• Stable or improving skin thickness without new striae, telangiectasia, or purpura at application sites
• Glucose and energy level remain at patient baseline when duration, quantity, and BSA stay within labeling limits

Escalate when misuse patterns or systemic corticosteroid toxicity appear—especially after prolonged use, occlusion, large BSA, or overlapping steroid products.

• New striae, paper-thin skin, purpura, or focal atrophy at treated sites while therapy continues
• Polyuria, thirst, fatigue, or confirmed hyperglycemia during high-absorption topical use
• Hypotension, severe fatigue, nausea, abdominal pain, or confusion after abrupt discontinuation—consider adrenal insufficiency
• Spreading warmth, pustules, honey-colored crusting, or fever suggesting secondary infection masked by steroids
• Diffuse rash, facial swelling, wheeze, or respiratory distress after application—evaluate for anaphylaxis or severe hypersensitivity
• Patient or caregiver continuing plastic-wrap occlusion, exceeding 2 weeks, or combining unsanctioned potent topical steroids

↔On a small screen, swipe or scroll sideways to see the full table.

Reviewed DailyMed prescribing information does not list a specific antidote for clobetasol overexposure. Management is supportive.

Topical overuse or systemic absorption

• Withdraw or reduce clobetasol per prescriber direction when toxicity or HPA suppression is suspected
• Monitor for adrenal insufficiency and hyperglycemia; provide supplemental systemic steroids if acute withdrawal signs develop—hydrocortisone or equivalent per prescriber and endocrine guidance
• Contact local poison control or toxicology services per facility protocol for significant exposure concerns
• Document grams used, duration, BSA, occlusion practices, and all concurrent corticosteroids

• Clobetasol vs clobetasone vs betamethasone—verify generic name and potency; super-high potency clobetasol is not interchangeable with medium-potency products
• 0.05% vs 0.025% clobetasol cream—different labeled indications and site restrictions; confirm strength on tube and MAR
• Topical clobetasol vs oral prednisone—duplicate therapy is a common home health reconciliation miss
• Temovate cream vs Temovate solution—same active ingredient but different vehicles and site suitability
• Patient-applied “more is better”—thick layers and plastic wrap drive absorption errors without prescriber oversight

↔On a small screen, swipe or scroll sideways to see the full table.

↔On a small screen, swipe or scroll sideways to see the full table.

Monitor

• Treated skin at each visit—erythema, plaque thickness, striae, atrophy, infection, and patient-reported burning
• Days of consecutive therapy and estimated grams per week against the 2-week / 50 g limits
• Blood glucose in diabetes or when duration, BSA, or occlusion exceeds labeling—use scheduled blood glucose monitoring per protocol
• Signs of HPA suppression: fatigue, weight gain, facial fullness, glucosuria, or abnormal adrenal testing when ordered
• All concurrent corticosteroids from every route at admission and home visits

Document

• Product, strength, sites treated, approximate BSA percentage, amount used, occlusion status, and patient/caregiver technique
• Start date and cumulative days of therapy; hold events and prescriber/pharmacy notifications
• Glucose trends, striae/atropy findings, and teaching provided on duration and quantity limits
• Lactation teaching when breast-adjacent dermatitis is treated

• Use a thin layer only on affected areas—do not exceed 2 consecutive weeks or 50 g in a week unless the prescriber explicitly changes the plan
• Do not cover with plastic wrap or tight dressings unless the prescriber and product labeling allow it
• Report new stretch marks, easy bruising, thin skin, increased thirst or urination, or unusual fatigue promptly
• Keep a list of every steroid product (prescription topicals, OTC creams, inhalers, pills) for each healthcare visit
• Breastfeeding: avoid nipple application; cleanse skin before nursing if treatment is nearby
• Do not stop abruptly after prolonged high-absorption use without prescriber guidance—ask about taper or stress-dose instructions

Do not apply and contact the prescriber or pharmacist when:

Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy. When HPA suppression is suspected, coordinate gradual withdrawal or supplemental steroids rather than abrupt unsupervised stop.

Practice NCLEX-style clinical judgment practice for clobetasol HPA suppression and topical misuse using a tabbed case (MAR, labs, history, nursing notes), then priority action, cue recognition (SATA), glucose and skin-trend interpretation, matrix urgency sorting, clinical judgment MCQ, and documentation cloze—recognise cues → analyse → prioritise → act → evaluate outcomes.

This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.

• Editorial Policy
• Medical Review Process
• Disclaimer

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.